Immediate action must be taken to ensure more effective and equitable implementation of cancer screening, according to a report released by the President’s Cancer Panel.
A study led by investigators at the University of Alabama at Birmingham and Nationwide Children’s Hospital has provided additional evidence of the efficacy of virotherapy for glioblastoma.
Researchers at Yale Cancer Center showed that inhibition of the CECR2 gene prevents triple-negative breast cancer from advancing or metastasizing.
UNC Lineberger Comprehensive Cancer Center researchers demonstrated that a novel combination of Pfizer’s Ibrance (palbociclib) and Millennium Pharmaceuticals’ sapanisertib, delivered in a nanoparticle formulation, extended the survival of mice with medulloblastoma.
A new risk score can identify men and women under age 50 most likely to develop colorectal cancer, according to an international study led by researchers at NYU Langone Health and the Laura and Isaac Perlmutter Cancer Center.
Results from the pivotal phase III KEYNOTE-775/Study 309 trial, evaluating the combination of Keytruda (pembrolizumab) plus Lenvima (lenvatinib) versus chemotherapy (treatment of physician’s choice of doxorubicin or paclitaxel) for patients with advanced endometrial carcinoma following at least one prior platinum-based regimen in any setting, showed the combination led to significantly longer progression-free survival and overall survival.
Positive results from the HIMALAYA phase III trial showed a single priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in overall survival versus Nexavar (sorafenib) as a first-line treatment for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localized treatment.
Performance data for a second-generation Cologuard (multi-target stool DNA) test showed an overall sensitivity of 95.2% for colorectal cancer at specificity of 92.4% for negative samples confirmed by colonoscopy.
A team of researchers with the UC Davis Comprehensive Cancer Center found that even with expanded access to Medi-Cal health coverage, Latino smokers in California continue to get less help than non-Latino white people quitting smoking.
Researchers at Fox Chase Cancer Center found that disparities in the incidence of head and neck cancer are driven by behavioral and environmental risk factors rather than race.
